To assess the individual contributions of the platelet glycoprotein (GP) Ilb/llla receptor and the a,& vitronectin receptor to platelet levels of fibrinogen and vitronectin, we analyzed the platelets from two groups of Glanzmann thrombasthenic patients: Iraqi-Jews, whose platelets lack both receptors, and Arab patients in Israel, whose platelets lack GPllb/llla, but have normal or increased numbers of a,p3 vitronectin receptors. The platelets from both thrombasthenic groups had profound deficiencies of fibrinogen, but the defect in the Iraqi-Jewish patients' platelets appeared to be slightly more severe. This finding indicates that GPllb/llla is the major determinant of platelet fibrinogen, presumably acting by receptor-mediated uptake, and that the a,& vit- v -300 pg/mL3') yields a ratio that may also be consistent with relative platelet enrichment.% Since we previously demonstrated that both GPIIb/IIIa and the a$3 vitronectin receptor on platelets can mediate in vitro interactions with vitronectin? we also analyzed the vitronectin content of platelets from these patients.
H fibrinogen, and comparison of the platelet and plasma concentrations ( -14 mg/lO" platelets v 3 mg/mL) suggests that fibrinogen may be concentrated in platelet^."^ The source of this fibrinogen is uncertain; early reports supported megakaryocyte synthesis,5.' but recent studies have both questioned the ability of megakaryocytes to synthesize fibrinogenss9 and provided support for an alternative mechanism involving endocytosis of plasma fibrin~gen.".'~ There is reason to suspect that the platelet glycoprotein (GP) IIb/IIIa receptor may mediate this endocytosis, because this receptor can bind fibrinogen under certain condition^'^ and platelet fibrinogen is markedly reduced in Glanzmann thrombasthenia, a disorder characterized by a deficiency of functional GPIIb/IIIa receptor^.'.^*^^-^^ The recent identification of a small number of q,p3 vitronectin receptors on human platelets"" raises the possibility that this receptor mediates fibrinogen uptake either in addition to, or instead of, GPIIb/IIIa, because the qfi3 receptor on other cells has been shown to bind fibrin~gen?"'~ Thus, the relative contributions of GPIIb/IIIa and the %fig vitronectin receptor have not been established.
vitronectin receptors on the platelets of patients with Glanzmann thrombasthenia in Israel and found that patients from the Iraqi-Jewish population are deficient in both GPIIb/IIIa and q,p3 vitronectin receptors, whereas patients from the Arab population are deficient in GPIIb/IIIa, but have normal or increased numbers of %fig In the present study, we compared the platelet fibrinogen content of patients from each population to assess the contributions of each receptor.
Vitronectin has also been identified in platelet^^*"^ and comparison of normal platelet and plasma concentrations (200 to 810 pg/lO'' v -300 pg/mL3') yields a ratio that may also be consistent with relative platelet enrichment.% Since we previously demonstrated that both GPIIb/IIIa and the a$3 vitronectin receptor on platelets can mediate in vitro interactions with vitronectin? we also analyzed the vitronectin content of platelets from these patients.
We have characterized the platelet GPIIb/IIIa and platelets have normal amounts of platelet vitronectin, whereas Iraqi-Jewish patients' platelets have nearly five times as much vitronectin as control or Arab patients' platelets. To account for these data, we propose a working hypothesis in which vitronectin is synthesized in megakaryocytes and the a,B3 vitronectin receptor is involved in transport of the protein out of megakaryocytes and/or platelets. Collectively, these observations suggest that in addition to their recognized roles in cell adhesion and the interaction of cells with extracellular proteins, integrin receptors may be important in protein trafficking into, and perhaps out of, platelets. 0 1991 by The American Society of Hematology.
MATERIALS AND METHODS
Patients and platelet preparation. For studies of platelet fibrinogen, eight patients from seven kindreds in the Iraqi-Jewish population and five patients from three kindreds in the Arab population were studied. For studies of platelet vitronectin, seven of the above patients from six kindreds in the Iraqi-Jewish population and the same five patients from the three kindreds in the Arab population were studied.
Blood from controls, four of the Iraqi-Jewish patients, and three of the Arab patients was drawn into a syringe containing 10 mmoI/L EDTA, 0.5 or 5.0 mmol/L leupeptin (Sigma, St Louis, MO), 2 mmol/L benzamidine (Sigma), 6 mmol/L N-ethylmaleimide, and 0.1 mmol/L tosyl-phenylethylchloromethyl-ketone (Sigma).
Platelet-rich plasma (PRP) was prepared by centrifugation and then the PRP was washed three times in buffer (0.15 mol/L NaC1, 0.01 mol/L Tris/HCI, pH 7.4) containing these same inhibitors. The platelets were finally resuspended to 2 to 3 x 10' platelets per microliter and solubilized by adding an equal volume of 3.3% sodium dodecyl sulfate (SDS), 6 mmol/L N-ethylmaleimide containing the above inhibitors, and heating to 100°C for 3 minutes. Solubilized platelet samples were kept frozen at -20°C or -80°C. Blood from the other four Iraqi-Jewish patients and two Arab patients was anticoagulated with 1/10 vol 3.8% sodium citrate. After PRP was prepared, EDTA (10 mmol/L final concentration) was added, and the samples were pelleted and washed twice in EDTA, pH 7.4). The samples were then solubilized in SDS as indicated above and stored at -20°C. Our previous studies indicated that GPIIb, but not GPIIIa, is particularly sensitive to in vitro proteolysis and that inhibitors are required to prevent the proteolysis"~"; in the present study, we found no differences in control platelets' fibrinogen and vitronectin with the different platelet preparation techniques described above.
To assess platelet fibrinogen, solubilized platelets were mixed 2 1 with a sample buffer containing 3.05% SDS, 0.18 mol/LTris/HCI, 30% glycerol, and 0.02% bromophenol blue, after which they were heated to 100°C for 3 minutes. These nonreduced Fibrinogen.
-340,000. In some experiments, gels were stained with Coomassie blue after partial electrophoretic transfer of proteins to a solid support (see below).
To obtain a semiquantitative estimate of platelet fibrinogen content, various amounts of control and patient platelet samples were electrophoresed on a single gel. The intensity of each myosin heavy-chain band (M, 200,000), which was taken as a reference protein indicative of the amount of platelet protein loaded onto the gel, was assessed by visual inspection and, in some experiments, densitometry (E-C Apparatus, St Petersburg, FL). After establishing the volume of each sample that contained equivalent amounts samples were then analyzed on a 1.5" thick gel containing a 1 x 10 cm 3% acrylamide stacking gel and a 5.4 x 10 cm 5% acrylamide resolving gel containing the discontinuous buffer system of Laemmli.." Gels were stained with Coomassie blue and the fibrinogen band was identified as a broad band migrating at M, of protein, these volumes, and fractions of these volumes, were electrophoresed on the same gel and the fibrinogen bands were assessed.
In other experiments, fibrinogen was identified by immunoblotting using a monoclonal antibody to fibrinogen (#311; American Diagnostica, Greenwich, CT). In these experiments, after gel electrophoresis, the resolved proteins were transferred to a polyvinylidene difluoride (PVDF) membrane (Immobilon-P; Millipore, Bedford, MA) using a semidry apparatus (LKB 21 17-250 Novablot; Bromma, Sweden) at approximately 1 mA/cm' of membrane for 90 to 270 minutes as previously described." The membranes were then reacted with 0.9% NaCI, 0.02 mol/L Tris/HCI, and 20 mmol/L sodium azide, pH 8.2, containing 5% bovine serum albumin to block unreacted sites. As an additional check that comparable amounts of protein had actually been electrophoresed, the gel was stained with Coomassie blue and the myosin heavychain band was assessed. Although some of the myosin heavy-chain was transferred to the PVDF membrane, enough remained in the gel to assess the equivalence of the protein loads.
To assess platelet vitronectin, the solubilized platelets were mixed with the above sample buffer, 2-mercaptoethanol was added to 5% (vol/vol), and the sample was heated to 100°C for 3 minutes before electrophoresis in a 3% polyacrylamide stacking virronecrin.
gel and a 7% polyacrylamide resolving gel. Electrophoretic transfer was accomplished as described above, except that it was allowed to proceed for only 90 minutes. Three different antibodies to vitronectin were used as the primary detection antibodies: (1) a murine monoclonal antibody" (kindly supplied by Dr Erica Asch, New York Medical College, as purified IgG at a concentration of 25 kg/mL) was used at a 1/50 dilution; (2) a commercial rabbit polyclonal antibody (Telios, La Jolla, CA) supplied as lyophilized serum after absorption with immobilized human plasma proteins (used at 1/100 dilution); and (3) a polyclonal antiserum prepared in our laboratory by immunizing New Zealand white rabbits with vitronectin purified by a modification of the method of Yatohgo et aV6 as previously described? with an additional purification step involving cutting the bands from a polyacrylamide gel and electroeluting (Centrilutor; Amicon, Danvers, MA) the vitronectin into 50 mmol/L TrislHCI, 384 mmol/L glycine, and 0.2% SDS. The primary antibodies were diluted in a buffer of 0.9% NaCI, 20 mmol/L TrislHCI, 20 mmol/L sodium azide, 0.1% bovine serum albumin (A-7638; Essentially Globulin Free, Sigma), and 1% goat serum, pH 8.2, and the incubation was carried out for 2 hours with gentle rocking at 22°C. To assess the specificity of the antibodies, in some experiments antibodies were preincubated with purified vitronectin prepared as previously described." In these studies, equal volumes of the diluted purified antibodies and the purified vitronectin (50 &mL) were incubated for approximately 15 minutes at 22°C before being added to the membranes. The immunoblots using the monoclonal antibody were developed with gold-labeled goat antibody to mouse IgG and those using the polyclonal antibody were developed with gold-labeled goat antibody to rabbit IgG. A mixture of two different gold-labeled antibodies (AuroProbe BL Plus at 1/133 dilution and AuroProbe One at 1/400, Janssen, Olen, Belgium) in the above 0.9% NaCl buffer containing 1% gelatin and 0.1% bovine serum albumin was used for each blot. The bands were enhanced with a silver stain (Intense BL, Janssen).
RESULTS
The results of gel electrophoresis studies on three Arab samples and five Iraqi-Jewish samples are shown in Fig 1. The fibrinogen band was easily identified as a broad band of M, -340,000 migrating between actinbinding protein (M, 260,000) and the sharp thrombospondin band (M, 450,000). Samples from all of the Arab and Iraqi-Jewish patients demonstrated a profound reduction in platelet fibrinogen (Fig 1A) . On close scrutiny, direct comparison of samples from Arab and Iraqi-Jewish patients suggested that the Arab samples contained slightly more fibrinogen than the Iraqi-Jewish samples (Fig 1A and B) . Semiquantitative data on the amount of platelet fibrinogen present based on Coomassie blue staining of various dilutions of patient and control samples indicated that the four Arab samples had between 2% and 11% of normal, whereas all four Iraqi-Jewish samples tested had significantly less than 3% of the control value (data not shown). Because the Coomassie blue staining technique is limited in sensitivity and specificity, we also studied control and patient samples with the more sensitive immunoblot technique using a monoclonal antibody to fibrinogen (Fig 1C) . The profound reduction in platelet fibrinogen in patients from both the Iraqi-Jewish and Arab patients was confirmed. In addition, there was no evidence of unusual lower M, bands in the patient samples, excluding the possibility
Fibrinogen.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From that the reduction in the M, 340,000 fibrinogen band was due to excessive proteolysis. When comparable amounts of platelet protein from patients from both populations were analyzed on a single gel, the fibrinogen bands in the Arab patients were slightly more intense than the fibrinogen bands in the Iraqi-Jewish patients ( Fig 1C) ; this supports the impression from the Coomassie blue studies that the platelet fibrinogen deficiency in Iraqi-Jewish patients may be somewhat more severe.
vitronectin. The results of the immunoblot studies using anti-vitronectin antibodies are shown in Fig 2. Samples from one control, three Iraqi-Jewish patients from three different kindreds, and three Arab patients from three different kindreds were electrophoresed at comparable protein loads as shown by the similarities in staining intensity of the myosin heavy-chain bands of the gel after immunoblotting (Fig 2A, upper panel) . The control sample (C) in the immunoblot using the monoclonal antibody to vitronectin (Fig 2A, lower panel) contained the characteristic vitronectin doublet of M , -65,000 and M, -75,000. In studies not shown, these bands migrated to exactly the same positions as plasma vitronectin tested under the same conditions. A very faint band of M, -45, OOO could also be observed both in platelets and plasma, corresponding to a minor plasma vitronectin band of the identical M, previ- The three Arab samples had bands that were comparable in intensity to those of the control samples. They differed from the control in the ratio of intensities of the M, -65,000 and M , -75,000 bands, but normal individuals are known to vary in this ratio as a function of a genetic polymorphism at amino acid 381 that controls the extent of in vivo However, the minor band of M, -45,000 appeared to be slightly more intense in the Arab patient samples than the control. Results with two additional Arab samples were similar to those depicted in Fig 2. In sharp contrast, the M, -65,000 and M, -75,000 bands in all three Iraqi-Jewish samples stained more intensly than did the bands in the control or Arab patient samples. In addition, the M, 45 ,000 band was dramatically more intense with the samples from all three Iraqi-Jewish patients. Similar results were observed with platelet samples from four additional Iraqi-Jewish patients.
To verify the results obtained with the monoclonal antibody to vitronectin, similar experiments were con- Platelet samples solubilized in SDS were reduced with 2-mercaptoethanol, electrophoresed into 7% polyacrylamide gels, and then transferred to a PVDF membrane. This resulted in the transfer of the majority of the lower M, bands, but only a minority of the higher M, bands. After transfer, the gel was stained with Coomasrie blue to assess whether comparable loads of protein were applied to each lane as judged by the intensity of the myosin heavy-chain band (M, 200,000); these stained gels are shown in the upper panels. The lower panels are the immunoblots of the transferred proteins after reaction with (A) a murine monoclonal antibody to vitronectin, (B) a rabbit polyclonal antibody to vitronectin obtained from Telios, and (C) the rabbit antibody t o vitronectin prepared in our laboratory. The membranes were then reacted with gold-labeled antibodies t o murine and rabbk IgG, respectively, and the reactive bands were enhanced with a silver reagent. Additional controls included control platelets reacted with vitronectin antibodies preincubated with purified vitronectin (Anti-Vn + Vn) (A, B, and C) and control platelets reacted with normal rabbit serum (B and C).
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From ducted with the polyclonal antiserum to vitronectin obtained from Telios (Fig 2B) . The control sample gave a pattern similar to that observed with the murine monoclonal antibody, except for the presence of a new strong band at M, -50,000. This band was also present when the platelets of four other controls were tested. Interestingly, this band was less intense in the platelets of all of the patients. The intensity of this M, -50,000 band was not diminished by preincubating the antiserum with our purified vitronectin preparation (Anti-Vn + Vn lane), raising the possibility that it was due to the presence of another protein in the immunizing antigen. To investigate this further, we prepared a polyclonal antiserum against our purified vitronectin. This antiserum did not recognize the M, -50,000 band in control platelets (Fig 2C) , supporting the hypothesis that the M, -50,000 band is neither vitronectin nor a proteolytic fragment of vitronectin. Simultaneous analysis of platelets and plasma using the Telios antiserum demonstrated that the M, -50,000 band is in plasma, as well as in platelets (data not shown). Studies are ongoing to establish the identity of theM, -50,000 protein; although it has an M, similar to that reported for plasminogen activator inhibitor-1 (PAI-1)F a protein that is known to associate with vitrone~tin,~.~' preliminary immunoblot studies using a monoclonal antibody to PAI-1 (American Diagnostica) have been negative. The vitronectin protein patterns with the patients' samples using both the Telios and Stony Brook antisera were virtually identical to those using the monoclonal antibody; the Arab samples gave bands comparable in intensity to the control, and the Iraqi-Jewish samples gave much more intense bands, with the M, -45,000 bands being especially notable (Fig 2B and C) . To estimate the relative increase in vitronectin content of Iraqi-Jewish platelets, various amounts of platelet protein from a control and a patient were electrophoresed on a single gel and the immunoblot intensities of the bands were compared. Figure 3 shows the results with the Telios antibody, but similar results were obtained using the Stony Brook polyclonal antibody. The staining intensities of the M, -65,000 and M, -75,000 bands of the patient's sample tested at a protein load of 20% Cjudged by the intensities of the myosin heavy-chain band) were only slightly less than the control sample at loo%, and the patients' sample at a protein load of 40% corresponded in intensity to the control at 200%, indicating that the patients' platelets contains almost five times as much vitronectin as the control platelets. Of note was that the intensity of the M, -45,000 band in the Iraqi-Jewish patient's platelets was similar to the M, -45,000 band in control platelets when the Iraqi-Jewish sample was diluted to give M , -65,000 and M, -75,000 bands that were comparable in intensity to that of the control. This indicates that the increased intensity of the M, 45 ,000 band in the Iraqi-Jewish samples was due to an increase in vitronectin content, rather than an increase in vitronectin proteolysis.
DISCUSSION
Data are mounting to support the hypothesis that platelet fibrinogen originates from plasma fibrinogen via receptormediated uptake by megakaryocytes and perhaps platelets.
(1) The weight of evidence indicates that megakaryocytes cannot synthesize fibrinogen? although at least in rats, mRNA for the y-chain of fibrinogen may be transiently expressed in immature megakaryocytes>' (2) Patients with Glanzmann thrombasthenia have markedly decreased platelet fibrin~gen.'.~,''.'~ (3) Administration of fibrinogen to an afibrinogemic patient resulted in a delayed and sustained increase in platelet fibrinogen level." (4) Administration of biotin-labeled fibrinogen to animals resulted in the uptake of the labeled fibrinogen into megakaryocyte and platelet granules." (5) The ratio of platelet to plasma fibrinogen exceeds that of other plasma proteins such as albumin and IgG, which are thought to be nonspecifically taken up by ~latelets.4.~~ (6) Continuous infusion into humans of an antibody that blocks both GPIIb/IIIa and the a$, vitronectin receptor (7E3)'2.23.26." results in a decrease in platelet fibrinogen after approximately 24 hours>' (7) Infusion of a snake venom containing the Arg-Gly-Asp (RGD) cell recognition sequence, a sequence that is known to block GPIIb/IIIa, the vitronectin receptor, and the GPIc/IIa (VLA-5) fibronectin receptor, prevented uptake of biotinlabeled fibrinogen into platelets." (8) Although the GPIIb/IIIa receptor is the most likely candidate receptor to mediate fibrinogen uptake, the identification of the a,@, vitronectin receptor on normal platelets2B?' opened the possibility that this receptor is responsible for fibrinogen uptake, in whole or in part, because this receptor is also known to bind to Moreover, none of the studies indicated above could unequivocally distinguish between GPIIb/IIIa and the a&, vitronectin receptor, because both the antibody and the peptide used may block both receptors and most Glanzmann thrombasthenia patients' platelets have not been characterized for a#, vitronectin receptor expression. We recently analyzed two groups of Glanzmann thrombasthenia patients, both of which have virtually no GPIIb/IIIa receptors," for a$, vitronectin receptor expression and found that the IraqiJewish patients' platelets have virtually no detectable a$, vitronectin receptors, whereas the Arab patients' platelets have normal or increased numbers of a$, vitronectin receptors." Our molecular biology studies of these patients are in accord with these findings, because all of the Iraqi-Jewish patients have the same defect in GPIIIa (p,) and three of the four Arab kindreds have the same defect in GPIIb. 4' In the present study, we found that both Iraqi-Jewish and Arab patients' platelets have profound deficiencies in platelet fibrinogen. There was a suggestion that the deficiency might be slightly less severe in the platelets from the Arab patients, but the differences were minor. Thus, at present, it appears that GPIIb/IIIa is the most important receptor in determining platelet fibrinogen, and the a$, vitronectin receptor plays little or no role. This is not surprising given the difference in receptor numbers on the platelet surface ( -45,000 GPIIb/IIIa receptors v -100 a$, vitronectin receptors).22 Disdier et all" reported on the platelet fibrinogen content in three patients with severe Glanzmann thrombasthenia. One patient's platelets had undetectable levels of fibrinogen and the other two had 6.4% and 10.8% of normal, values similar to those in our study. Immunoblot studies on these patients were not provided, so it is not possible to assess whether there was a correlation with a$, vitronectin receptor expression.
Platelet For personal use only. on October 22, 2017. by guest www.bloodjournal.org From platelets, but there was a loss of the M, 75,000 band in thrombin releasates and platelets treated with freezing and thawing. The release of platelet vitronectin by different doses of thrombin was similar to, but not identical with, the release of platelet factor IV and PAI-1. Maximal release by thrombin was approximately 70% to 80% of total platelet vitronectin. Finally, they provided evidence that platelet vitronectin and platelet PAI-1 are complexed, at least when studied after release from platelets, but the fraction of each protein that exists in complexwith the other protein was not determined.
Asch and Podack" performed immunoblot studies of platelet vitronectin and found a major 75-Kd band. They further showed that platelet vitronectin became expressed on the platelet surface when gel-filtered platelets were stimulated by thrombin, but not epinephrine, indicating the need to induce the release reaction.
Our data indicate that the platelets of patients with Glanzmann thrombasthenia are not deficient in vitronectin and therefore it is unlikely that platelet vitronectin relies on uptake from plasma mediated by GPIIb/IIIa or the vitronectin receptor. However, it remains possible that uptake takes place via an alternative receptor(s) mechanism. In particular, because at least a fraction of plasma vitronectin may exist in complex with PAI-1, a receptor for this latter protein might lead to uptake of vitronectin as well. At present, no platelet receptor for PAI-1 has been identified. Alternatively, and perhaps more likely, it is possible that platelet vitronectin derives from megakaryocyte synthesis. Preliminary immunofluorescence studies by Kanz et a1 of bone marrow megakaryocytes and megakaryocytes grown in culture are consistent with this hypothe~is.4~
The most striking and unexpected finding in our studies was the consistently observed increase in platelet vitronectin in patients with Glanzmann thrombasthenia from the Iraqi-Jewish population as compared with controls and patients from the Arab population. Semiquantitative studies suggested that Iraqi-Jewish patient platelets may contain as much as 400% to 500% of the control value. Because the Iraqi-Jewish patients lack the a$, vitronectin receptor, it is interesting to speculate whether this receptor is involved in transport of vitronectin out of the megakaryocyte or platelet. This would be a novel function for an integrin receptor, because most attention has focused on integrins as mediating cell adhesion and the interaction between cells and extracellular proteins. However, it can be viewed as simply the reverse of the process by which fibrinogen is internalized. Support for this hypothesis will require direct evidence for synthesis by megakaryocytes and transport of vitronectin out of megakaryocytes or platelets mediated by a$,; studies of cell lines with megakaryocytic features might provide suggestive evidence.
The physiologic function of platelet vitronectin is unknown. The recent observations that vitronectin deposited in the extracellular matrix can serve to localize PAI-1'' and to stabilize its active c~n f o r m a t i o n~~,~~ raises the possibility that local release of platelet vitronectin in thrombi could inhibit fibrinolysis. This could be one factor in the resistance of platelet-rich thrombi to thrombolysi~.~~ Finally, most recently Ehrlich et a1 demonstrated that when PAI-1 is complexed with vitronectin, it can neutralize thrombin effe~tively,~' raising the possibility that platelet release of vitronectin may also act to modulate thrombus formation by this mechanism. The complexity of these potential interactions deduced from in vitro experiments reinforces the need to try to establish the sequence of events that actually occur during in vivo thrombus formation. 
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